About:
BrainsWay is dedicated to developing and providing advanced solutions for brain disorders. The company was established in 2003, and became a public company traded on the Tel-Aviv Stock Exchange in January 2007. BrainsWay’s flagship technology, which is based on Deep Transcranial Magnetic Stimulation (TMS), launches a new era in brain disorder treatment.
BrainsWay’s treatment is based on patents filed by the U.S. National Institutes of Health (NIH), and by the company. The company holds an exclusive license from the NIH for the patent and for its unique technology.
BrainsWay’s treatment is FDA-cleared for treating depressive episodes in adult patients suffering from Major Depressive Disorder, who failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current episode (FDA 510(k) No. K122288). BrainsWay is also approved in Canada for the treatment of Major Depressive Disorder (Health Canada Licence No. 90504).
BrainsWay runs clinical research programs with leading scientists worldwide, collaborating with prominent institutions and researchers in clinical trials covering various neuropsychiatric and neuroscience applications.
The company’s technology has already helped thousands of people worldwide in both private clinics and clinical studies. It has also been enthusiastically embraced by leading research institutions worldwide, with over 60 clinical trials held around the globe.
Why Now?
Post-Traumatic Stress Disorder: Finally, once the worst of the corona pandemic will be behind us and the world will start to regain a sense of stability, symptoms of PTSD will likely begin to appear. The remnants of a traumatic or deeply destabilizing occurrence has been shown to linger well beyond the actual event, and continue generations into the future.
At present, there are a number of proven treatments for anxiety-based conditions, such as social anxiety or OCD; depressive disorders such as MDD; and PTSD. Such treatments, which include psychotherapy, medication and non-invasive treatment options, have been shown to target adverse symptoms and help bring about a sense of relief.
Technically :
Only Above 8.32!
Not holding yet.
Not for a suggestion!
BrainsWay is dedicated to developing and providing advanced solutions for brain disorders. The company was established in 2003, and became a public company traded on the Tel-Aviv Stock Exchange in January 2007. BrainsWay’s flagship technology, which is based on Deep Transcranial Magnetic Stimulation (TMS), launches a new era in brain disorder treatment.
BrainsWay’s treatment is based on patents filed by the U.S. National Institutes of Health (NIH), and by the company. The company holds an exclusive license from the NIH for the patent and for its unique technology.
BrainsWay’s treatment is FDA-cleared for treating depressive episodes in adult patients suffering from Major Depressive Disorder, who failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current episode (FDA 510(k) No. K122288). BrainsWay is also approved in Canada for the treatment of Major Depressive Disorder (Health Canada Licence No. 90504).
BrainsWay runs clinical research programs with leading scientists worldwide, collaborating with prominent institutions and researchers in clinical trials covering various neuropsychiatric and neuroscience applications.
The company’s technology has already helped thousands of people worldwide in both private clinics and clinical studies. It has also been enthusiastically embraced by leading research institutions worldwide, with over 60 clinical trials held around the globe.
Why Now?
Post-Traumatic Stress Disorder: Finally, once the worst of the corona pandemic will be behind us and the world will start to regain a sense of stability, symptoms of PTSD will likely begin to appear. The remnants of a traumatic or deeply destabilizing occurrence has been shown to linger well beyond the actual event, and continue generations into the future.
At present, there are a number of proven treatments for anxiety-based conditions, such as social anxiety or OCD; depressive disorders such as MDD; and PTSD. Such treatments, which include psychotherapy, medication and non-invasive treatment options, have been shown to target adverse symptoms and help bring about a sense of relief.
Technically :
Only Above 8.32!
Not holding yet.
Not for a suggestion!